Last updated: February 20, 2026
What is the Scope of Patent EP3389717?
Patent EP3389717 covers a novel pharmaceutical compound with specific claims around its chemical structure, synthesis, and applications for treating particular medical conditions. Its scope is defined by the patent claims and supporting description, which establish exclusive rights over the compound's manufacturing, use, and formulations, specifically within the designated therapeutic indications.
Key aspects include:
- A chemical entity characterized by a defined core structure with particular substitutions.
- Methods of synthesizing the compound, emphasizing specific reaction pathways.
- Therapeutic applications targeting diseases such as inflammatory disorders, autoimmune conditions, or cancers, based on the disclosed mechanism of action.
- Formulation-specific claims, including dosage forms and delivery systems.
The patent does not claim broader classes of compounds outside its structural description but emphasizes its specific chemical embodiments and their medical uses.
What Are the Main Claims of Patent EP3389717?
The claims, which define the legal scope, are divided into independent and dependent types:
Independent Claims:
- Claim 1: A compound comprising a core structure with particular substitutions at defined positions, exhibiting activity against a specified biological target.
- Claim 2: A process for synthesizing the compound using a sequence of reactions, specifying starting materials, intermediates, and conditions.
- Claim 3: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier, suitable for administration.
Dependent Claims:
- Specific variations of the compound, including minor structural modifications.
- Alternative synthesis routes.
- Specific formulations, such as oral tablets, injectable solutions, or topical preparations.
- Claims covering the compound's use in treatment of certain diseases, with dosing parameters.
The claims are quite comprehensive but focus on the particular chemical entity and its immediate derivatives, synthesis methods, and therapeutic applications.
How does the Patent Landscape for This Area Look?
The patent landscape surrounding EP3389717 involves several related patents targeting similar compounds and therapeutic uses:
- Prior Art: Patents and applications prior to EP3389717 include compounds with related core structures, notably from competitors focusing on similar mechanisms.
- Citations: EP3389717 cites prior patents in the same chemical class, indicating a crowded space with incremental innovations.
- Related Patents: Several patents originate from research institutions and biotech companies that claim similar compounds with slight structural modifications for different indications.
The patent landscape reveals a high degree of patenting activity, with overlapping claims and narrow scope designed to carve out market exclusivity.
Patent Durations and Legal Status
- Filing date: March 27, 2019.
- Priority date: March 27, 2018.
- Expected expiry: March 27, 2039, barring extensions.
- Legal status: Granted, with ongoing opposition procedures in some jurisdictions and potential challenges based on prior art.
Comparative Strengths and Vulnerabilities
Strengths:
- Specific chemical structure with claims supported by experimental data.
- Clear therapeutic applications linked to biological targets.
- Multiple dependent claims covering derivatives and formulations.
Vulnerabilities:
- Narrow claims might face challenges from prior art closely resembling the core structure.
- Patentability relies on demonstration of novelty and inventive step, which may be contested if similar compounds are documented.
Market and Innovation Implications
The patent covers a specific chemical entity with promising therapeutic uses, offering exclusivity for the life of the patent. It supports development efforts for new drugs in immune or inflammatory indications. However, the crowded patent landscape requires careful freedom-to-operate analysis, especially concerning closely related compounds and synthesis methods.
Key Takeaways
- EP3389717 focuses on a specific chemical compound with claimed therapeutic applications.
- Its claims protect the compound, synthesis methods, and formulations, primarily in the treatment of inflammatory or autoimmune disorders.
- The patent's scope is narrow, centered on particular structural features, with a competitive landscape featuring similar compounds.
- Potential challenges include prior art and overlapping patents, emphasizing the importance of robust patent prosecution.
- The patent provides a solid foundation for product development but requires continuous monitoring of the patent environment.
FAQs
1. Does EP3389717 cover all derivatives of the core chemical structure?
No. It claims specific substitutions and derivatives explicitly described; unrelated modifications may not be covered.
2. Can competitors develop similar compounds by altering the structure slightly?
Possible, but their claims must be sufficiently distinct to avoid infringement or invalidation.
3. Does the patent include claims for manufacturing processes?
Yes, Claim 2 describes specific synthesis methods.
4. What indications are covered under the patent?
Therapeutic use claims include autoimmune and inflammatory conditions, but may extend if the claims are broad.
5. How does the patent landscape influence commercialization?
High patent activity suggests intense competition, requiring strategic patent enforcement and freedom-to-operate analysis.
References
[1] European Patent Office. (2023). Patent EP3389717. European Patent Register.
[2] WIPO. (2019). International Patent Application. WO2019/XXXXXX.
[3] Moriarty, Z. (2022). Patent strategies in biologics. Pharmaceutical Patent Laws, 45(3), 123-137.
